CompanyGraphShenzhen Edge Medical Co., Ltd.
2675 · HKEX · China
Price data from its R5Z listing on FSX, quoted in EUR
edgemed.cnFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.84B, above the global median of $1.15B
- FinancialsLow earnings quality
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
14.43BHKD1.84B · vs all stocks (USD)
Revenue (TTM)
530.35MCNY67.61M · vs all stocks (USD)
Profit Margin
-19.44%vs Medical Devices peers
52-Week Change
-36.11%vs all stocks
Market Capitalization
14.43BHKD1.84B · vs all stocks (USD)
Enterprise Value
15.81BHKD2.02B · vs all stocks (USD)
Forward P/E
58.15xvs Medical Devices peers
Price to Sales (TTM)
31.67xvs Medical Devices peers
Price to Book (MRQ)
9.56xvs Medical Devices peers
Enterprise to Revenue
29.81xvs Medical Devices peers
Enterprise to EBITDA
-138.55xvs Medical Devices peers
Profit Margin
-19.44%vs Medical Devices peers
Operating Margin
-4.40%vs Medical Devices peers
Return on Assets (TTM)
-5.34%vs Medical Devices peers
Return on Equity (TTM)
-7.21%vs Medical Devices peers
Revenue (TTM)
530.35MCNY67.61M · vs all stocks (USD)
Revenue per Share (TTM)
1.27CNYUpdated Aug 19, 2026Quarterly Revenue Growth
136.10%vs Medical Devices peers
Gross Profit (TTM)
349.89MCNY44.61M · vs all stocks (USD)
EBITDA (TTM)
-114.12MCNY-14.55M · vs all stocks (USD)
Net Income (TTM)
-103.12MCNY-13.15M · vs all stocks (USD)
Operating Cash Flow (TTM)
-226.11MCNY-28.83M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-224.15MCNY-28.58M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
455.71MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
155.06MCNYFY2025 · Dec 31, 2025Gross Profit
300.65MCNYFY2025 · Dec 31, 2025Operating Income
-103.11MCNY-15.29M · vs all stocks (USD)
Pre-tax Income
-88.61MCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
-88.61MCNYFY2025 · Dec 31, 2025EBIT
-88.07MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-76.82MCNYFY2025 · Dec 31, 2025Research & Development
185.20MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
225.32MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.43MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
541.00KCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
-88.61MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-119.74MCNYFY2025 · Dec 31, 2025Free Cash Flow
-123.05MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
86.04MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-88.61MCNYFY2025 · Dec 31, 2025Stock-based Compensation
28.14MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-4.89MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-989.00KCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-53.40MCNYFY2025 · Dec 31, 2025Capital Expenditures
-3.30MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-138.00KCNYFY2025 · Dec 31, 2025Net Acquisitions
-222.00KCNYFY2025 · Dec 31, 2025Purchase of Investments
-951.87MCNYFY2025 · Dec 31, 2025Sale of Investments
1.12BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
168.93MCNYFY2025 · Dec 31, 2025Other Financing Charges
-708.00KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-708.00KCNYFY2025 · Dec 31, 2025Shares Outstanding
387.72MSharesUpdated Aug 19, 2026Float Shares
150.40MSharesUpdated Aug 19, 2026% Held by Insiders
53.84%vs all stocks
% Held by Institutions
35.07%vs all stocks
Total Cash (MRQ)
1.07BCNY136.93M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.35CNYUpdated Aug 19, 2026Total Debt (MRQ)
11.51MCNY1.47M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0083xvs Medical Devices peers
Current Ratio (MRQ)
8.11xvs Medical Devices peers
Book Value per Share (MRQ)
3.87CNYUpdated Aug 19, 2026Total Assets
1.39BCNY205.51M · vs all stocks (USD)
Total Current Assets
1.33BCNYFY2025 · Dec 31, 2025Total Liabilities
187.03MCNYFY2025 · Dec 31, 2025Total Non-current Assets
51.39MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
22.59MCNYFY2025 · Dec 31, 2025Total Current Liabilities
164.44MCNYFY2025 · Dec 31, 2025Cash
86.04MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
86.04MCNYFY2025 · Dec 31, 2025Other Short-term Investments
836.85MCNYFY2025 · Dec 31, 2025Accounts Receivable
213.45MCNYFY2025 · Dec 31, 2025Inventory
136.11MCNYFY2025 · Dec 31, 2025Accounts Payable
22.80MCNYFY2025 · Dec 31, 2025Short-term Debt
4.25MCNYFY2025 · Dec 31, 2025Long-term Debt
5.64MCNYFY2025 · Dec 31, 2025Common Stock (Book)
360.00MCNYFY2025 · Dec 31, 2025Retained Earnings
-809.73MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.20BCNY177.77M · vs all stocks (USD)
52-Week Low
33.62HKDUpdated Aug 19, 202652-Week High
73.70HKDUpdated Aug 19, 202652-Week Change
-36.11%vs all stocks
50-Day MA
39.04HKDUpdated Aug 19, 2026200-Day MA
51.95HKDUpdated Aug 19, 2026Avg 10-Day Volume
273.28KSharesUpdated Aug 19, 2026Avg 30-Day Volume
371.93KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.2700CNYUpdated Aug 19, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.98
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.84B, above the global median of $1.15BNotable
Market cap (USD): 1,839,938,160.445Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Chipscreen Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
Novocure Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ascletis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Mirxes Holding Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Zaggle Prepaid Ocean Services Ltd.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity ConfigurationOperating Income Growing With Multi-Year Revenue Growth
Orbbee Inc.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity ConfigurationOperating Income Growing With Multi-Year Revenue Growth
Rambus Inc.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity ConfigurationOperating Income Growing With Multi-Year Revenue Growth